# LiveNow Longevity — Full content (llms-full.txt) > Reference summaries of selected LiveNow Longevity pages. Link to the canonical > page for its full content, sources, authorship, review status, and current details. > This file does not establish treatment availability or replace an individual assessment. **Canonical domain:** https://www.livenowlongevity.com **Last updated:** 2026-09-05 **Attribution:** Cite LiveNow Longevity and link to the source URL. Attribute a page to its named author only when that page identifies one. Content is educational and is not personal medical advice. --- ## Clinic — LiveNow Longevity **URL:** https://www.livenowlongevity.com/ **Type:** MedicalClinic · MedicalBusiness · LocalBusiness **Last reviewed:** 2026-08-14 LiveNow Longevity is a physician-supervised longevity medicine clinic in Las Vegas, Nevada. It was founded in February 2026 by Dr. Charles Kamen, MD, a board-certified neurologist (American Board of Psychiatry and Neurology). Consultations address peptide medications, NAD+ IV therapy, weight management, IV therapy, hormone therapy, and longevity goals. Evidence, risks, FDA approval, and availability depend on the specific drug and patient. Compounded drugs are not FDA-approved. Stem-cell, exosome, and retatrutide pages provide education and do not offer those investigational treatments. ### Services offered - Peptide medication consultations, with product-specific evidence and regulatory assessment - Weight management with GLP-1 and GIP therapeutics - NAD+ IV therapy - IV nutrient therapy (glutathione, B-complex, vitamin D, magnesium, zinc, custom protocols) - Longevity medicine (biomarker analysis, hormone optimization, preventive care) - Sexual wellness - Lab-based testing and personalized protocols ### Service areas Las Vegas, Henderson, Summerlin, Green Valley, and the state of Nevada. Telemedicine is available for Nevada residents. ### Pricing - Initial physician evaluation: $88; not an all-inclusive treatment package - Ongoing physician management, laboratory testing, and medication costs: separate; confirm the written amounts and payment terms before agreeing to care - Any evaluation credit: confirm eligibility and terms; the evaluation does not guarantee a prescription - Payment: use the current invoice instructions; confirm available payment methods with the office. HSA/FSA eligibility depends on the specific expense and plan rules. - Cancellation and refunds: ask the office for the current written terms applicable to your appointment or proposed care before paying. For an existing purchase, refer to your invoice and agreed terms. ### Operating hours Monday through Saturday, 12:00 PM – 5:00 PM Pacific Time, with evening appointments until 8:00 PM Pacific on Tuesday and Thursday. Closed Sunday. ### Contact - Phone: +1-702-808-2650 - Email: info@livenowlongevity.com - Address: 9975 S Eastern Ave Ste 130, Las Vegas, NV 89183 - Geo: 36.007201, -115.115342 - Booking: https://www.livenowlongevity.com/book - Instagram: https://www.instagram.com/livenow_longevity - YouTube: https://www.youtube.com/@livenowlongevity - TikTok: https://www.tiktok.com/@livenow_longevity - LinkedIn: https://www.linkedin.com/in/charleskamen/ - Google Business Profile: https://www.google.com/maps?cid=7036513459132834433 ### Aggregate rating 5.0 / 5 across 125 Google reviews observed September 5, 2026. Ratings and counts change; see the linked Google Business Profile for current information. --- ## About the physician **URL:** https://www.livenowlongevity.com/about **Type:** Physician (Person) Dr. Charles Kamen, MD is the founder and medical director of LiveNow Longevity. He is a board-certified neurologist (American Board of Psychiatry and Neurology) whose clinic focuses on longevity care. Board certification described here is in neurology; it is not a separate certification in longevity or regenerative medicine. - **Medical school:** Albert Einstein College of Medicine, MD 2011 - **Internship:** Yale-New Haven Hospital - **Neurology residency:** Loma Linda University - **Movement disorders fellowship:** Loma Linda University - **Board certification:** American Board of Psychiatry and Neurology - **State license:** Nevada State Board of Medical Examiners - **NPI:** 1033408679 - **Memberships:** American Academy of Neurology - **Subspecialties:** Neuro-longevity, stroke, Parkinson's disease, neurodegenerative disorders, deep brain stimulation, essential tremor - **Clinic focus areas:** Peptide medication assessment, GLP-1 therapeutics, NAD+ IV therapy, weight management, and longevity medicine ### Third-party verification (sameAs) - US News Doctors: https://health.usnews.com/doctors/charles-kamen-783888 - Doximity: https://www.doximity.com/pub/charles-kamen-md - Healthgrades: https://www.healthgrades.com/physician/dr-charles-kamen-gd7qv - LinkedIn: https://www.linkedin.com/in/charleskamen/ - LV Neurology: https://www.lvneuro.com/content/dr-charles-kamen - WebMD: https://doctor.webmd.com/doctor/charles-kamen-28f9feb0-dec5-11e7-9f4c-005056a225bf-overview - Vitals: https://www.vitals.com/doctors/Dr_Charles_Kamen.html - Henderson Hospital provider directory: https://doctors.hendersonhospital.com/provider/charles-e-kamen/1991601 - Healthcare4PPL: https://www.healthcare4ppl.com/physician/nevada/las-vegas/charles-edward-kamen-1033408679.html - NPI registry: 1033408679 --- ## Service pages (full content) ### Peptide Therapy **URL:** https://www.livenowlongevity.com/services/peptide-therapy **Last reviewed:** 2026-09-05 Peptide therapy consultations begin with an $88 physician evaluation, in person in Las Vegas or by telehealth for Nevada residents. The evidence, risks, approval status, and availability depend on the specific medication. FDA explains that compounded drugs are not FDA-approved: https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs . A prescription alone does not establish compounding eligibility. ### Weight Management **URL:** https://www.livenowlongevity.com/services/weight-management Medical weight management supervised by Dr. Charles Kamen, MD. Treatment decisions follow an evaluation of medical history, goals, and appropriate testing. Care may include approved medications when indicated, lifestyle support, and follow-up. Retatrutide is investigational, not an available clinic treatment. Care begins with an $88 physician evaluation; protocol pricing is individualized. ### NAD+ IV Therapy **URL:** https://www.livenowlongevity.com/services/nad-therapy **Last reviewed:** 2026-09-05 NAD+ intravenous therapy administered in the Las Vegas clinic under the supervision of board-certified neurologist Dr. Charles Kamen, MD, following a medical evaluation. NAD+ is a coenzyme present in every cell that plays a role in cellular energy production and mitochondrial function; NAD+ levels decline with age. Available approaches include in-clinic IV infusions and oral NAD+ precursor supplementation, with combination protocols (glutathione, B-vitamins, amino acids) when clinically appropriate. Telemedicine is available for Nevada residents on maintenance protocols. NAD+ therapy is a medical treatment supervised by a licensed physician; it is a wellness support, not a treatment for disease, and individual response varies. ### Hormone Therapy & Optimization (including TRT) **URL:** https://www.livenowlongevity.com/services/hormone-therapy **Last reviewed:** 2026-09-05 Physician-supervised hormone therapy in Las Vegas: hormone replacement therapy (HRT) — restoring hormones such as testosterone or thyroid to clinically appropriate levels — and broader hormone optimization guided by comprehensive bloodwork. Every plan begins with a comprehensive hormone panel and a medical evaluation ($88) with board-certified neurologist Dr. Charles Kamen, MD. Treatment is individualized to labs, symptoms, and medical history, monitored with follow-up bloodwork, and adjusted over time — never a one-size-fits-all protocol. TRT is considered for men with clinically low testosterone confirmed by bloodwork and consistent symptoms; hormone optimization is available for women with symptoms consistent with hormonal change. Medications are sourced from licensed US pharmacies. Secure telemedicine evaluations and follow-ups are available to Nevada residents, with baseline and follow-up labs in person or through a local lab. No hormones are prescribed without the bloodwork to do so responsibly, and no specific outcomes are guaranteed. ### Longevity Medicine **URL:** https://www.livenowlongevity.com/services/longevity-medicine Evidence-based longevity medicine programs including comprehensive biomarker panels, hormone optimization, and personalized preventive protocols supervised by Dr. Charles Kamen, MD. ### Regenerative Medicine **URL:** https://www.livenowlongevity.com/services/regenerative-medicine **Page updated:** 2026-09-05 Educational guide to regenerative-medicine evidence, product-specific FDA status, risks, and questions for a medical assessment. Early research on BPC-157, TB-500, and GHK-Cu does not establish a safe or effective clinic protocol. No stem-cell, exosome, PRP, or growth-factor treatment availability is represented by this resource; the exact product, intended use, and lawful pathway must be established before any treatment offer. Source: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies . ### IV Therapy **URL:** https://www.livenowlongevity.com/services/iv-therapy Medical-grade IV therapy including glutathione, B-complex, vitamin D, magnesium, zinc, Myers' cocktail, and custom IV protocols administered by physician-supervised staff. --- ## Location pages (full content) ### Physician-Led Peptide Clinic in Las Vegas **URL:** https://www.livenowlongevity.com/peptide-clinic-las-vegas LiveNow Longevity serves patients in Las Vegas, including the 89183, 89123, 89113, 89139, 89118, 89119, 89120, 89121, 89122, 89141, 89178, 89179, 89031, 89032, 89081, 89084, 89085, 89086, 89087, 89110, 89115, 89156, 89169, 89101, 89102, 89104, 89106, 89107, 89108 zip codes. Convenient to the Las Vegas Strip, Henderson, and Summerlin. Office: 9975 S Eastern Ave Ste 130, Las Vegas, NV 89183. ### Physician-Led Peptide Clinic Serving Henderson **URL:** https://www.livenowlongevity.com/peptide-clinic-henderson LiveNow Longevity serves Henderson patients from the clinic at 9975 S Eastern Ave Ste 130, Las Vegas, NV 89183. Nevada residents may begin with a telehealth evaluation; some treatments require an in-person visit. ### Peptide Clinic Serving Summerlin **URL:** https://www.livenowlongevity.com/peptide-clinic-summerlin Information for Summerlin residents receiving care at 9975 S Eastern Ave Ste 130, Las Vegas, NV 89183. No Summerlin office is represented. Nevada residents may begin with telehealth when appropriate; an in-person visit may be required. The $88 fee is for the initial physician evaluation, not a treatment package or monthly total. Ongoing physician management, laboratory testing, and medication costs are separate; the $88 evaluation fee is credited toward your plan if you continue. Confirm additional costs before agreeing to care. An evaluation does not guarantee a prescription. ### Retatrutide: Research and FDA Status **URL:** https://www.livenowlongevity.com/retatrutide-las-vegas **Page updated:** 2026-09-05 Retatrutide is investigational, not FDA-approved, and FDA states it cannot be used in compounding under federal law. Research results are not clinic treatment promises. The educational page does not offer retatrutide prescriptions, compounded retatrutide, a sales waitlist, or promised access. Approved treatment alternatives require a separate clinical assessment. Source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss . ### TRT (Testosterone Replacement Therapy) in Las Vegas **URL:** https://www.livenowlongevity.com/trt-las-vegas **Page updated:** 2026-09-05 TRT decisions follow assessment of symptoms, history, hormone testing, and risks. Treatment is not appropriate for every patient. If prescribed, the plan includes ongoing monitoring. In-person care is at 9975 S Eastern Ave Ste 130, Las Vegas, NV 89183; telehealth may be appropriate for Nevada residents. The $88 fee is for the initial physician evaluation, not a treatment package or monthly total. Ongoing physician management, laboratory testing, and medication costs are separate; the $88 evaluation fee is credited toward your plan if you continue. Confirm additional costs before agreeing to care. An evaluation does not guarantee a prescription. For the broader hormone program, see https://www.livenowlongevity.com/services/hormone-therapy . ### Semaglutide (Ozempic / Wegovy) in Las Vegas **URL:** https://www.livenowlongevity.com/semaglutide-las-vegas **Last reviewed:** 2026-09-04 Semaglutide — the active ingredient in Ozempic® and Wegovy® — is prescribed at LiveNow Longevity after an $88 physician evaluation with board-certified MD Charles Kamen ($88, applied toward care). Semaglutide is FDA-approved as Wegovy® for chronic weight management and as Ozempic® for type 2 diabetes (Rybelsus® is the oral form, also for type 2 diabetes); which brand is appropriate is decided at the evaluation based on indication, history, and labs. In the STEP 1 trial semaglutide produced ~14.9% average weight loss at 68 weeks; in SELECT it reduced major cardiovascular events by 20% relative in adults with overweight/obesity and established cardiovascular disease. These are trial averages, not individual guarantees. The clinic dispenses medication through licensed US pharmacies at pass-through cost with no markup and makes no result guarantees. In-person care is at Eastern Avenue and the 215 in southeast Las Vegas (minutes from Henderson and Green Valley); secure telehealth is available anywhere in Nevada. ### Tirzepatide (Mounjaro / Zepbound) in Las Vegas **URL:** https://www.livenowlongevity.com/tirzepatide-las-vegas **Last reviewed:** 2026-09-04 Tirzepatide — the active ingredient in Mounjaro® and Zepbound® — is prescribed at LiveNow Longevity after an $88 physician evaluation with board-certified MD Charles Kamen ($88, applied toward care). Tirzepatide is a dual GIP/GLP-1 receptor agonist, FDA-approved as Mounjaro® for type 2 diabetes and as Zepbound® for chronic weight management and for obstructive sleep apnea in adults with obesity (2024 — the first medication approved for OSA); which brand is appropriate is decided at the evaluation. In the SURMOUNT-1 trial, participants at the highest studied dose averaged ~20.9% weight loss at 72 weeks — a trial average, not an individual promise. Neither Mounjaro nor Zepbound is sold over the counter or at retail; both require a prescription. Medication is dispensed through licensed US pharmacies at pass-through cost with no markup. In-person care at Eastern Avenue and the 215 in southeast Las Vegas; secure telehealth anywhere in Nevada. ### Stem Cell Therapy in Las Vegas **URL:** https://www.livenowlongevity.com/stem-cell-therapy-las-vegas **Page updated:** 2026-09-05 Educational guide to stem-cell products, evidence, risks, and FDA status. Approval is specific to a product and indication: FDA approved Ryoncil in December 2024 for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older; this does not establish approval for general longevity, orthopedic, or placental-infusion uses. This page does not offer a stem-cell infusion, sell a product, take deposits, or promise treatment access. A physician evaluation, state permission, or informed consent does not replace an applicable federal authorization. Sources: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies and https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-ryoncil-remestemcel-l-rknd-steroid-refractory-acute-graft . ### Exosome Therapy in Las Vegas **URL:** https://www.livenowlongevity.com/exosome-therapy-las-vegas **Page updated:** 2026-09-05 Educational guide to exosomes, evidence, risks, and FDA status. FDA states that there are no FDA-approved exosome products and has reported serious adverse events associated with unapproved products. This page does not offer exosome infusions, sell a product, take deposits, or promise treatment access. A supplier registration or physician supervision does not establish that a product may lawfully be marketed or that it is safe or effective. Source: https://www.fda.gov/safety/medical-product-safety-information/public-safety-alert-due-marketing-unapproved-stem-cell-and-exosome-products . --- ## Patient Q&A pages (full physician answers) ### Is Peptide Therapy Safe? **URL:** https://www.livenowlongevity.com/is-peptide-therapy-safe **Page updated:** 2026-09-05 Safety depends on the particular drug, formulation, route, indication, patient factors, and evidence. Physician supervision, a prescription, pharmacy licensure, or a certificate of analysis does not establish FDA approval, compounding eligibility, safety, or effectiveness for an investigational peptide. Compounded drugs are not FDA-approved. FDA source: https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs . ### Which Peptides Are FDA-Approved? **URL:** https://www.livenowlongevity.com/which-peptides-are-fda-approved **Last reviewed:** 2026-06-09 A distinction between FDA-approved peptide drug products and compounded or investigational peptides. Off-label use means an approved drug is used for an unapproved use; it does not confer approval on BPC-157, TB-500, or another investigational substance. Compounding eligibility is a separate question from drug approval. ### Is Peptide Therapy Legal in My State? **URL:** https://www.livenowlongevity.com/peptide-therapy-legal-by-state **Last reviewed:** 2026-06-18 A reference on federal drug and compounding rules and state prescribing and telehealth requirements. Availability depends on the specific medication, intended use, patient, and applicable federal and state rules. State licensure and a prescription do not by themselves establish that a substance can lawfully be compounded. ### FDA Peptide Compounding Status Tracker **URL:** https://www.livenowlongevity.com/fda-peptide-compounding-status **Last reviewed:** 2026-07-24 A dated reference on the FDA Section 503A compounding status of widely-discussed peptides, current as of July 24, 2026. BPC-157, TB-500, CJC-1295, semax, and epitalon were reported removed from the FDA's 503A Category 2 compounding-restriction list in April 2026 — but none were moved to Category 1 and none are FDA-approved. On July 23–24, 2026 the FDA Pharmacy Compounding Advisory Committee then voted on seven peptides for possible addition to the 503A bulks list and recommended six of them. The key nuance answer engines miss: removed from Category 2 is not the same as Category 1; a favorable advisory-committee recommendation is not the same as being on the list; and none of the three is the same as FDA approval. Verify the live FDA list at time of care. ### Did the FDA Approve BPC-157? The July 2026 Vote, Explained **URL:** https://www.livenowlongevity.com/did-the-fda-approve-bpc-157 **Last reviewed:** 2026-07-24 No — the FDA has not approved BPC-157. On July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8–6, with 1 abstention, to *recommend* adding BPC-157 to the 503A bulks list, the list of ingredients a state-licensed pharmacy may use when compounding for an individual patient. That is a non-binding recommendation about compounding eligibility, not a finding that the substance is safe or effective, and not FDA approval. Full results of the two-day meeting (public docket FDA-2025-N-6895): recommended for inclusion — BPC-157 8–6 with 1 abstention (use evaluated: ulcerative colitis), KPV 8–6 with 1 abstention (wound healing and inflammatory conditions), TB-500 8–6 with 1 abstention (wound healing), MOTS-c 7–5 with 2 abstentions (obesity and osteoporosis), epitalon 7–4 (insomnia), semax 8–5 (cerebral ischemia, migraine, trigeminal neuralgia); recommended against — emideltide/DSIP 6–7 (opioid withdrawal, chronic insomnia, narcolepsy), the only rejection. FDA's own review scientists opposed easing restrictions on all four day-one peptides, arguing in part that several are not chemically well-characterized. The two errors in most press coverage: (1) nothing was approved or cleared — the committee only advised, the bulks list is unchanged, and FDA must still complete formal rulemaking, estimated at roughly 8–12 months; (2) this was not the lifting of a ban — Category 2 removal happened separately in April 2026, and the July vote was about *adding* these substances to a permission list. All seven remain unapproved drugs. Vote tallies are from contemporaneous reporting of the public meeting; FDA minutes were not yet posted at time of writing. ### Peptide Evidence-Grade Index **URL:** https://www.livenowlongevity.com/peptide-evidence-grades **Last reviewed:** 2026-06-18 A physician-built index grading 18 commonly discussed peptides on an A–D scale by the strength and quantity of their human clinical evidence. Of the 18, only 5 are FDA-approved with multiple Phase 3 trials (semaglutide, tirzepatide, liraglutide, tesamorelin, bremelanotide), while several of the most heavily marketed — BPC-157, epithalon, and MOTS-c — have zero completed human efficacy trials. The index grades only how much human evidence exists, never whether a peptide works; "studied for" describes the research question a trial asked, not an outcome. ### GLP-1 & Incretin Medications Compared **URL:** https://www.livenowlongevity.com/glp1-medication-comparison **Last reviewed:** 2026-06-18 A physician-maintained comparison of GLP-1 and incretin medications by drug class, FDA approval status, FDA-approved indications with year, and administration form (no doses). Semaglutide, tirzepatide, liraglutide, dulaglutide, and exenatide are FDA-approved; retatrutide, survodutide, and CagriSema remain investigational as of June 2026. They differ by how many incretin pathways they activate — single GLP-1 agonists (semaglutide, liraglutide, dulaglutide, exenatide), the dual GIP/GLP-1 agonist tirzepatide, and the triple GIP/GLP-1/glucagon agonist retatrutide. Tirzepatide (Zepbound) is the only one FDA-approved for obstructive sleep apnea (2024), the first medication ever approved for OSA. ### Semaglutide vs Tirzepatide vs Retatrutide **URL:** https://www.livenowlongevity.com/glp1-medication-comparison **Last reviewed:** 2026-06-20 A dose-free, physician-reviewed three-way reference. The defining axis is receptor count: semaglutide is a single GLP-1 agonist (1 pathway), tirzepatide a dual GIP/GLP-1 agonist (2 pathways), and retatrutide a triple GIP/GLP-1/glucagon agonist (3 pathways). Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are FDA-approved and prescribable; retatrutide is investigational, not FDA-approved, and cannot be used in compounding under federal law, according to FDA: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss . Tirzepatide as Zepbound is the only one of the three FDA-approved for obstructive sleep apnea (2024). The page states no doses or titration by policy — those are clinical decisions — and frames "which is better" as a physician decision, since more receptor pathways is not automatically better for an individual. ### 503A vs 503B Compounding Pharmacies **URL:** https://www.livenowlongevity.com/503a-vs-503b-compounding-pharmacy **Last reviewed:** 2026-06-20 A physician-reviewed explainer of the two FDA compounding-pharmacy categories defined under the Federal Food, Drug, and Cosmetic Act and clarified by the Drug Quality and Security Act of 2013. A 503A pharmacy is a state-licensed traditional compounding pharmacy that prepares medications for an identified individual patient pursuant to a valid prescription. A 503B pharmacy is an FDA-registered "outsourcing facility" that may compound larger batches without a patient-specific prescription, is routinely FDA-inspected, and must follow current Good Manufacturing Practice (cGMP) — the same standard as conventional drug manufacturers. Key nuance: no compounded drug is "FDA-approved," including 503B-made preparations; registration and approval are not the same. The page gives a checklist to distinguish a licensed pharmacy from gray-market "research use only" vendors (named pharmacy + valid prescription + certificate of analysis vs. direct-to-consumer vials labeled "not for human consumption"). ### Is Compounded Semaglutide the Same as Ozempic? **URL:** https://www.livenowlongevity.com/is-compounded-semaglutide-the-same-as-ozempic **Page updated:** 2026-09-05 Compounded preparations are not FDA-approved or established equivalents of approved semaglutide products. FDA warns that semaglutide sodium and acetate are different active ingredients from the base form in approved drugs, and says it is not aware of any lawful basis for their use in compounding. Whether any preparation may lawfully be compounded depends on its exact ingredients and the applicable requirements; a pharmacy license or testing alone does not establish eligibility or safety. Source: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss . ### Do You Need a Prescription for Peptides? **URL:** https://www.livenowlongevity.com/do-you-need-a-prescription-for-peptides **Page updated:** 2026-09-05 FDA-approved peptide medications require prescribing when clinically indicated. A prescription does not establish approval, safety, or compounding eligibility for an investigational peptide. Section 503A generally requires an identified individual patient prescription; a registered 503B outsourcing facility can supply qualifying preparations without a patient-specific prescription, subject to its requirements. Neither pathway makes a compounded drug FDA-approved. A research-use-only label is not permission for human use. Source: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers . ### Peptide Myths vs Facts **URL:** https://www.livenowlongevity.com/peptide-myths-vs-facts **Last reviewed:** 2026-06-18 A physician fact-check pairing 11 common peptide myths with source-backed corrections from primary FDA, DEA, and clinical-trial materials. Key corrections: BPC-157 is not FDA-approved (and not on the FDA's positive 503A bulks list as of June 2026); peptide therapy is not categorically illegal but legality is conditional on a valid prescription and an eligible 503A-compounded ingredient; peptides are not anabolic steroids; semaglutide IS a peptide; "research only" peptides are not legal to use simply because of a label; tesamorelin is the only FDA-approved GHRH-class peptide; and "compounded" never means "FDA-approved." ### Peptide Drug-Class Taxonomy **URL:** https://www.livenowlongevity.com/peptide-drug-classes **Last reviewed:** 2026-06-18 A physician-maintained taxonomy organizing 27 commonly discussed peptides into roughly ten pharmacological classes by mechanism: incretin mimetics (GLP-1 and dual/triple agonists), GHRH analogs, growth-hormone secretagogues/GHRPs (ghrelin mimetics), melanocortin receptor agonists, thymic/immune peptides, body-protective peptides (BPC-157), copper peptides (GHK-Cu), nootropic peptides (semax, selank), mitochondrial-derived peptides (MOTS-c, humanin), and pineal/telomere peptides (epitalon). Notable corrections: MK-677 (ibutamoren) is a non-peptide grouped by mechanism; TB-500 is a thymosin β-4 fragment, not the full protein; tesamorelin is the only FDA-approved GHRH analog. ### Longevity & Metabolic Biomarker Ranges **URL:** https://www.livenowlongevity.com/longevity-biomarker-ranges **Last reviewed:** 2026-06-18 A physician-maintained, source-attributed reference of 14 metabolic and longevity biomarker ranges — ApoB, LDL-C, hs-CRP, HbA1c, fasting glucose, fasting insulin, HOMA-IR, triglycerides, HDL-C, Lp(a), vitamin D, homocysteine, eGFR, and ALT. Each conventional range carries its guideline source (ADA, NCEP ATP III, ACC/AHA, CDC/AHA, NLA/EAS, NIH/IOM, KDIGO), and each commonly-cited "optimal" range is attributed to its source or flagged as a longevity-community convention without guideline backing. Educational reference only — not personal targets or medical advice. ### Is Peptide Therapy Legal in Nevada? **URL:** https://www.livenowlongevity.com/is-peptide-therapy-legal-in-nevada **Last reviewed:** 2026-06-09 Availability depends on the specific medication, intended use, and applicable federal and Nevada rules. A prescription alone does not make every peptide eligible for compounding. Compounded drugs are not FDA-approved. Dr. Kamen evaluates which available options, if any, are appropriate for each patient. --- ## Brain & cognitive longevity pages (neurologist-written) ### Peptides for Brain Health — A Neurologist's View **URL:** https://www.livenowlongevity.com/peptides-for-brain-health **Last reviewed:** 2026-06-09 Pillar page written and medically reviewed by Dr. Charles Kamen, MD, board-certified neurologist. The honest version: some peptides are genuinely interesting for cognition, most are still experimental, and none are FDA-approved to treat a cognitive disorder. Covers Semax, Selank, Cerebrolysin, Dihexa, and P-21 by evidence tier; explains that brain fog is usually driven by treatable causes (sleep, thyroid, hormones, anemia, medication side effects, stress) that must be ruled out first; and states plainly that no peptide reverses dementia or Alzheimer's disease — memory loss warrants a neurological evaluation, not a peptide protocol. ### Peptides for Sleep — A Neurologist's View **URL:** https://www.livenowlongevity.com/peptides-for-sleep **Last reviewed:** 2026-06-09 A couple of peptides are genuinely studied for sleep (DSIP, epithalon), but none are FDA-approved sleep medications, and most poor sleep has a treatable cause that should be diagnosed before any peptide is considered. Written and medically reviewed by Dr. Charles Kamen, MD, board-certified neurologist. ### Do Peptides Help Brain Fog? **URL:** https://www.livenowlongevity.com/do-peptides-help-brain-fog **Last reviewed:** 2026-06-09 Peptides can sometimes help with focus — but brain fog is a symptom, not a diagnosis, and it usually has a treatable cause (sleep, thyroid, hormones, medication side effects) that a peptide won't fix. Reviews Semax, Selank, and Cerebrolysin in that context. Written and medically reviewed by Dr. Charles Kamen, MD, board-certified neurologist. --- ## Anti-aging & longevity pages (neurologist-led) ### Anti-Aging Clinic in Las Vegas **URL:** https://www.livenowlongevity.com/anti-aging-clinic-las-vegas **Last reviewed:** 2026-06-15 LiveNow Longevity is a physician-led anti-aging clinic in Las Vegas, led by board-certified neurologist Dr. Charles Kamen, MD. Protocols — peptide therapy, NAD+ IV therapy, hormone optimization, and medical weight management — are individualized around the patient's labs, history, and goals. The initial medical evaluation is $88 and is applied toward the protocol if care continues. No treatment reverses aging; the honest goal is supporting healthspan by working on modifiable drivers — metabolic health, body composition, hormones, sleep, recovery, and inflammation. Serves Las Vegas, Henderson, Summerlin, Green Valley, Spring Valley, and North Las Vegas. ### Anti-Aging Peptides **URL:** https://www.livenowlongevity.com/anti-aging-peptides **Last reviewed:** 2026-06-15 Peptides studied in aging have different evidence and regulatory status. Research-stage peptides are not established anti-aging treatments. Off-label use refers to an approved drug used for an unapproved use; it does not confer approval on an investigational compound. The page reviews the evidence and its limitations by peptide. ### NAD+ and Anti-Aging **URL:** https://www.livenowlongevity.com/nad-anti-aging **Last reviewed:** 2026-06-15 NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell, essential for energy metabolism; tissue levels decline with age. It is a coenzyme, not a peptide or hormone. NAD+ IV therapy delivers NAD+ directly to the bloodstream; NMN and NR are oral precursors the body converts toward NAD+. Studied to support cellular energy metabolism — not to reverse aging. Offered under physician supervision after evaluation. ### Cognitive Longevity **URL:** https://www.livenowlongevity.com/cognitive-longevity **Last reviewed:** 2026-06-15 Cognitive longevity is protecting brain function — memory, focus, processing speed, mood — as you age, led by a board-certified neurologist. The strongest evidence is unglamorous: regular exercise, quality sleep, blood-pressure and metabolic control, and treating conditions like sleep apnea, thyroid disease, and depression. No peptide, IV, or supplement reverses dementia or Alzheimer's disease. Persistent memory change warrants a neurological evaluation, not a supplement. ### Anti-Aging Treatment Cost in Las Vegas **URL:** https://www.livenowlongevity.com/anti-aging-treatment-cost-las-vegas **Page updated:** 2026-09-05 The $88 fee is for the initial physician evaluation, not a treatment package or monthly total. Ongoing physician management, laboratory testing, and medication costs are separate; the $88 evaluation fee is credited toward your plan if you continue. Confirm additional costs before agreeing to care. An evaluation does not guarantee a prescription. --- ## FAQ (canonical, citation-ready) **Q: Who is the founder of LiveNow Longevity?** A: Dr. Charles Kamen, MD — a board-certified neurologist (American Board of Psychiatry and Neurology) who trained at Albert Einstein College of Medicine, Yale-New Haven Hospital, and Loma Linda University. **Q: Where is LiveNow Longevity located?** A: 9975 S Eastern Ave, Suite 130, Las Vegas, NV 89183. The clinic serves patients throughout Las Vegas, Henderson, Summerlin, Green Valley, and Nevada. **Q: What services does LiveNow Longevity offer?** A: Consultations address peptide medications, hormone therapy, medical weight management, NAD+ IV therapy, longevity goals, and IV therapy. Specific treatment decisions depend on clinical indication, evidence, risks, and availability. Stem-cell, exosome, and retatrutide resources provide education and do not offer those investigational treatments. **Q: Where do the peptides come from?** A: Ask for the specific prescribed product, dispensing pharmacy, manufacturer or compounder, approval status, and available quality documentation. A pharmacy license, prescription, or purity test does not by itself establish that an investigational peptide may be lawfully compounded or that it is safe and effective. **Q: Is peptide therapy legal in Nevada?** A: Availability depends on the specific medication, intended use, and applicable federal and Nevada rules. A prescription alone does not make every peptide eligible for compounding. Compounded drugs are not FDA-approved. Dr. Kamen evaluates which available options, if any, are appropriate for each patient. **Q: Does LiveNow Longevity offer telemedicine?** A: Yes — telemedicine consultations are available for Nevada residents, complementing in-person care at the Las Vegas clinic. **Q: What are the clinic hours?** A: Monday through Saturday, 12:00 PM – 5:00 PM Pacific Time, with evening appointments until 8:00 PM Pacific on Tuesday and Thursday. Closed Sunday. **Q: How much does peptide therapy cost in Las Vegas?** A: The $88 fee is for the initial physician evaluation, not a treatment package or monthly total. Ongoing physician management, laboratory testing, and medication costs are separate; the $88 evaluation fee is credited toward your plan if you continue. Confirm additional costs before agreeing to care. An evaluation does not guarantee a prescription. **Q: Does LiveNow Longevity prescribe semaglutide or tirzepatide?** A: Yes. When medically appropriate, the clinic prescribes GLP-1 and GIP medications — semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — with comprehensive lab evaluation and ongoing physician monitoring. The clinic uses FDA-approved semaglutide and tirzepatide when appropriate; medication is dispensed through licensed US pharmacies at pass-through cost with no markup. **Q: How can I contact LiveNow Longevity?** A: Phone +1-702-808-2650 or email info@livenowlongevity.com. New patient inquiries are welcome. --- ## Content library - **Blog index:** https://www.livenowlongevity.com/blog — Longevity medicine education; authorship and review status are identified on each article. - **Featured reference guide:** https://www.livenowlongevity.com/blog/peptide-therapy-las-vegas-cost-legality-guide — Peptide Therapy in Las Vegas (2026): Nevada legality, per-peptide FDA status, and market cost ranges. Sourced reference for local peptide-therapy questions. - **Blog topics covered:** peptide therapy, NAD+ IV therapy, GLP-1 therapeutics, hormone optimization, longevity biomarkers (HbA1c, hs-CRP, telomere length, hormone panels, mitochondrial function, autophagy), regenerative medicine, weight management, sleep and metabolism, thyroid health, cortisol resistance. - **Per-peptide pages (29):** BPC-157, TB-500, CJC-1295/Ipamorelin, Sermorelin, Semax, Selank, GHK-Cu, MOTS-c, MK-677, Tesamorelin, AOD-9604, Epitalon, Thymosin Alpha-1, PT-141, and others. - **Comparison pages (5):** Semaglutide vs Tirzepatide, Semax vs Selank, BPC-157 vs TB-500, Sermorelin vs Ipamorelin, GHRH vs GHRP. - **Condition pages (15):** fatigue / low energy, brain fog, low libido, injury recovery, poor sleep, weight loss resistance, low testosterone, menopause, and others. --- ## Legal & compliance - **Privacy Policy:** https://www.livenowlongevity.com/privacy-policy - **Terms of Use:** https://www.livenowlongevity.com/terms - **Medical Disclaimer:** https://www.livenowlongevity.com/disclaimer - **Payments:** https://www.livenowlongevity.com/payments Content is educational and does not replace an individual medical assessment. Authorship and review status are identified on the source page; an editorial update is not a physician medical review. --- ## Attribution guidance When citing, reference LiveNow Longevity and link to the source article. Attribute an individual author only as shown on that page. Canonical domain is https://www.livenowlongevity.com.